HUP9900609A2 - Antibacterial composition for oral administration - Google Patents

Antibacterial composition for oral administration

Info

Publication number
HUP9900609A2
HUP9900609A2 HU9900609A HUP9900609A HUP9900609A2 HU P9900609 A2 HUP9900609 A2 HU P9900609A2 HU 9900609 A HU9900609 A HU 9900609A HU P9900609 A HUP9900609 A HU P9900609A HU P9900609 A2 HUP9900609 A2 HU P9900609A2
Authority
HU
Hungary
Prior art keywords
stone
water
cefditoren pivoxil
oral administration
composition
Prior art date
Application number
HU9900609A
Other languages
Hungarian (hu)
Inventor
Kenichi Abe
Toshihiro Kikkoji
Chikako Murakami
Masato Ota
Hiroyuki Yamaguchi
Original Assignee
Meiji Seika Kaisha, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Kaisha, Ltd. filed Critical Meiji Seika Kaisha, Ltd.
Publication of HUP9900609A2 publication Critical patent/HUP9900609A2/en
Publication of HUP9900609A3 publication Critical patent/HUP9900609A3/en
Publication of HU224922B1 publication Critical patent/HU224922B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Abstract

A találmány őrális beadásra alkalmas új, antibakteriális kőmpőzícióravőnatkőzik, amely cefditőren pivőxil és egy vízőldható kazeinsókeverékét tartalmazza. A kőmpőzícióból, amelyben gyengébb a cefditőrenpivőxil keserű íze, a cefditőren pivőxil vízben könnyebben őldódik ki,és nagyőbb százalékős kiőldódás érhető el a cefditőren pivőxil vízzelvaló kiőldásakőr. A kőmpőzíció őrális beadásakőr a cefditőrenkőmpőnensnagymértékben felszívódik az emésztőcsatőrnában. A kőmpőzícióban acefditőren pivőxil - kazeinsó tömegarány előnyösen 1 : 0,1 és 1 : 4közötti. A találmány másődik váltőzata szerint az előbbi kőmpőzíciótővábbi összetevőként egy vízőldható pőlifőszfőrsavas sót tartalmaz.Ezáltal a cefditőrenpivőxil-kőmpőnens nagymértékű vízőldhatósága akkőris megmarad, ha a kőmpőzíciót szélsőséges körülmények között tárőlják. ŕThe invention is a new, antibacterial stone suppository suitable for oral administration, which contains a mixture of cefditoren pivoxil and a water-soluble casein salt. From the stone position, in which the bitter taste of cefditoren pivoxil is weaker, cefditoren pivoxil dissolves more easily in water, and a higher percentage of dissolution can be achieved with cefditoren pivoxil in water. Cefditőrenkom is largely absorbed in the alimentary canal after oral administration. The mass ratio of acefdithiorene pyloxyl to casein salt in the stone composition is preferably between 1:0.1 and 1:4. According to a variant of the invention, the former contains a water-soluble polyphosphoric acid salt as an additional component of the stone composition. As a result, the high water solubility of the cefditorenpivoxil stone component is maintained even if the stone composition is stored under extreme conditions. ŕ

HU9900609A 1995-10-13 1996-10-14 Antibacterial composition of cefditoren pivoxil for oral administration HU224922B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP26584795 1995-10-13
PCT/JP1996/002967 WO1997013516A1 (en) 1995-10-13 1996-10-14 Antibacterial composition for oral administration

Publications (3)

Publication Number Publication Date
HUP9900609A2 true HUP9900609A2 (en) 1999-07-28
HUP9900609A3 HUP9900609A3 (en) 2001-04-28
HU224922B1 HU224922B1 (en) 2006-04-28

Family

ID=17422903

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9900609A HU224922B1 (en) 1995-10-13 1996-10-14 Antibacterial composition of cefditoren pivoxil for oral administration

Country Status (16)

Country Link
US (1) US5958915A (en)
EP (1) EP0862915B1 (en)
KR (1) KR100311576B1 (en)
CN (1) CN1102046C (en)
AR (1) AR004014A1 (en)
AT (1) ATE214930T1 (en)
BR (1) BR9610836A (en)
CA (1) CA2234426C (en)
DE (1) DE69620220T2 (en)
ES (1) ES2174109T3 (en)
HK (1) HK1016477A1 (en)
HU (1) HU224922B1 (en)
MX (1) MX9802849A (en)
PT (1) PT862915E (en)
TW (1) TW458778B (en)
WO (1) WO1997013516A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999034832A1 (en) * 1998-01-07 1999-07-15 Meiji Seika Kaisha Ltd. Crystallographically stable amorphous cephalosporin compositions and process for producing the same
WO2000025752A1 (en) * 1998-11-02 2000-05-11 Church, Marla, J. Multiparticulate modified release composition
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
AU2002224053A1 (en) * 2000-11-21 2002-06-03 Kyorin Pharmaceutical Co. Ltd. Dry syrup preparations
AU2256702A (en) * 2000-12-01 2002-06-11 Kyowa Hakko Kogyo Kk Composition improved in solubility or oral absorbability
US20030060451A1 (en) * 2001-05-29 2003-03-27 Rajneesh Taneja Enhancement of oral bioavailability of non-emulsified formulations of prodrug esters with lecithin
MXPA03010945A (en) 2001-05-29 2004-02-27 Tap Pharmaceutical Prod Inc Enhancement of oral bioavailability of non-emulsified formulation of prodrug esters with lecithin.
WO2003097102A1 (en) * 2002-05-22 2003-11-27 Shionogi & Co., Ltd. Pharmaceutical preparation improved in dissolving property of drug slightly soluble in water
AUPS303202A0 (en) * 2002-06-20 2002-07-11 Pacific Biolink Pty Limited Protein based oral lubricant
WO2004030673A1 (en) * 2002-10-02 2004-04-15 Meiji Seika Kaisha, Ltd. Antibacterial medicinal composition of enhanced oral absorptivity
PT1671635E (en) * 2003-10-08 2012-01-17 Meiji Seika Pharma Co Ltd Noncrystalline antibacterial composition containing cefditoren pivoxil
JP2005162696A (en) * 2003-12-04 2005-06-23 Nichiko Pharmaceutical Co Ltd Cefditoren pivoxil pharmaceutical preparation excellent in dissolution property
AU2005306867B2 (en) 2004-11-16 2011-09-08 3M Innovative Properties Company Dental fillers and compositions including phosphate salts
DE602005023509D1 (en) 2004-11-16 2010-10-21 3M Innovative Properties Co DENTAL FILLERS, METHOD, COMPOSITIONS USING A CASEINATE
KR101366911B1 (en) 2004-11-16 2014-02-24 쓰리엠 이노베이티브 프로퍼티즈 컴파니 Dental fillers including a phosphorus-containing surface treatment, and compositions and methods thereof
JP2008520565A (en) 2004-11-16 2008-06-19 スリーエム イノベイティブ プロパティズ カンパニー Dental composition comprising calcium and phosphorus releasing glass
CA2612994A1 (en) 2005-06-08 2006-12-08 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising cefditoren
US20080069879A1 (en) * 2006-05-02 2008-03-20 Ravishekhar Bhiwgade Stable solid dosage form containing amorphous cefditoren pivoxil and process for preparation thereof
WO2010068359A1 (en) 2008-12-11 2010-06-17 3M Innovative Properties Company Surface-treated calcium phosphate particles suitable for oral care and dental compositions
TR201000688A2 (en) * 2010-01-29 2011-08-22 B�Lg�� Mahmut Effervescent formulations containing cefaclor and clavulanic acid as active ingredient.
EP2595631A4 (en) * 2010-07-23 2013-08-28 Lupin Ltd Pharmaceutical compositions of cefditoren pivoxil
EP3244879A1 (en) 2015-01-16 2017-11-22 Ögün, Yusuf Toktamis Cefditoren pivoxil compositions with improved stability and production methods thereof
CN105663058A (en) * 2016-02-01 2016-06-15 济南康和医药科技有限公司 Cefditoren pivoxil nanoparticle pharmaceutical preparation and preparation method

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5936609A (en) * 1982-08-26 1984-02-28 Nitto Electric Ind Co Ltd Adhesive application pharmaceutical
JPS59184122A (en) * 1983-03-31 1984-10-19 Nitto Electric Ind Co Ltd Acrylic plaster
JPS60102168A (en) * 1983-11-08 1985-06-06 Tsukishima Shokuhin Kogyo Kk Production of food enriched with eicosapentaenoic acid
IE58487B1 (en) * 1984-09-07 1993-09-22 Kaisha Maiji Seika New cephalosporin compounds and the production thereof
JPH0678234B2 (en) * 1988-04-19 1994-10-05 明治製菓株式会社 Antibacterial composition for oral administration
JPH0635394B2 (en) * 1989-02-28 1994-05-11 雪印乳業株式会社 Method for improving drug solubility and absorption
JPH0717866A (en) * 1993-06-16 1995-01-20 Meiji Seika Kaisha Ltd Medicinal composition
JPH0840907A (en) * 1994-08-03 1996-02-13 Meiji Seika Kaisha Ltd Cephalosporin injection

Also Published As

Publication number Publication date
ATE214930T1 (en) 2002-04-15
US5958915A (en) 1999-09-28
CN1202110A (en) 1998-12-16
TW458778B (en) 2001-10-11
DE69620220T2 (en) 2002-11-28
HUP9900609A3 (en) 2001-04-28
HU224922B1 (en) 2006-04-28
CA2234426C (en) 2003-07-08
PT862915E (en) 2002-09-30
WO1997013516A1 (en) 1997-04-17
BR9610836A (en) 1999-07-13
ES2174109T3 (en) 2002-11-01
HK1016477A1 (en) 1999-11-05
CA2234426A1 (en) 1997-04-17
AR004014A1 (en) 1998-09-30
EP0862915B1 (en) 2002-03-27
CN1102046C (en) 2003-02-26
EP0862915A4 (en) 1998-11-11
KR19990064137A (en) 1999-07-26
MX9802849A (en) 1998-11-30
EP0862915A1 (en) 1998-09-09
KR100311576B1 (en) 2001-12-28
DE69620220D1 (en) 2002-05-02

Similar Documents

Publication Publication Date Title
HUP9900609A2 (en) Antibacterial composition for oral administration
BR9916835A (en) Controlled-release galantamine composition
ATE302588T1 (en) DENTAL PRODUCT AGAINST TARTER AND RELATED METHOD
ATE328851T1 (en) MAGNESIUM AMMONIUM PHOSPHATE CEMENTS, THEIR PRODUCTION AND USE
BG104644A (en) Novel macrolides
HUP0300731A2 (en) Valsartan salts, process for their preparation and pharmaceutical compositions thereof
HUP0002316A2 (en) Flash-melt oral dosage formulation
BG103945A (en) Derivatives of 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a
HUP0401811A2 (en) Medicinal composition improved in solubility in water and process for its preparation
ES2158537T3 (en) DERIVATIVES OF CYCLOPROPILALCANOIC ACIDS.
MY129234A (en) Oral pharmaceutical forms of administration with a delayed action with tramadol.
PL348492A1 (en) Novel alpha-crystalline form of t-butylamine salt of perindopril, method of obtaining same and pharmacological compositions containing it
HUP0201907A2 (en) Timed dual release dosage forms comprising a short acting hypnotic or a salt
HUP0101411A2 (en) A pharmaceutical preparation comprising an angiotensin ii type 2 receptor agonist, and use thereof
HUP0001922A2 (en) Pyrazolo[4,3-c]-pyridine derivatives, pharmaceutical compositions thereof against insulin resistance, intermediates and process for their preparation
WO2003000692A3 (en) Oxytocin agonists
HUP0003571A2 (en) 6,9-bridged erythromycin derivatives
ATE215817T1 (en) SOLID DRUGS CONTAINING MILTEFOSINE FOR ORAL ADMINISTRATION IN THE TREATMENT OF LEISHMANIASIS
MY119090A (en) Synthetic polysaccharides, process for their preparation and pharmaceutical compositions containing them
IL41686A (en) Taste-improving formulations of oral penicillins
HUP0402006A2 (en) Method for the formation of ibuprofen crystals and their use for preparation of pharmaceutical compositions
HUP0002106A2 (en) Aromatic sulfonates of trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1h-dibenz-[2,3:6,7]oxepino[4,5-c]pyrrole and pharmaceutical compositions containing it
AP9801377A0 (en) Tricyclic erythromycin derivatives.
EP1285660A4 (en) Zinc-supplementary compositions for oral administration
CA2477773A1 (en) A stable diclofenac-tromethamine composition for the topical treatment of oropharyngeal cavity disorders

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: MEIJI SEIKA PHARMA CO., LTD., JP

Free format text: FORMER OWNER(S): MEIJI SEIKA KAISHA, LTD., JP